Jane Street’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-4,972
Closed -$86K 5107
2015
Q4
$86K Buy
4,972
+2,964
+148% +$70.7K ﹤0.01% 3818
2015
Q3
$42K Sell
2,008
-710
-26% -$24.3K ﹤0.01% 3450
2015
Q2
$135K Sell
2,718
-6,708
-71% -$401K ﹤0.01% 3366
2015
Q1
$738K Buy
9,426
+3,889
+70% +$241K 0.01% 1649
2014
Q4
$336K Buy
5,537
+3,095
+127% +$155K ﹤0.01% 1790
2014
Q3
$104K Sell
2,442
-11,543
-83% -$620K ﹤0.01% 2356
2014
Q2
$864K Buy
13,985
+12,136
+656% +$706K 0.01% 1005
2014
Q1
$120K Buy
+1,849
New +$125K ﹤0.01% 2483

Other funds holding OREX

Jane Street's OREX Position: Q1 2016 in Review

Jane Street sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 4,972 shares — an estimated $86K sold.

Jane Street first reported a position in OREX in Q1 2014 and held it in 8 quarters. The position peaked at $864K in Q2 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Jane Street reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Jane Street sold 4,972 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $86K.
  • Jane Street first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 8 quarters.
  • Jane Street's Orexigen Therapeutics, Inc. position peaked at $864K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Jane Street's 13F filing for Q1 2016, filed 17 May 2016.